Ensign Peak Advisors’s Arcutis Biotherapeutics ARQT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $28.1M | Buy |
2,001,439
+13,050
| +0.7% | +$183K | 0.05% | 259 |
|
|
2025
Q1 | $31.1M | Sell |
1,988,389
-385,751
| -16% | -$6.03M | 0.06% | 233 |
|
|
2024
Q4 | $33.1M | Sell |
2,374,140
-42,672
| -2% | -$594K | 0.06% | 234 |
|
|
2024
Q3 | $22.5M | Buy |
2,416,812
+283,110
| +13% | +$2.63M | 0.04% | 306 |
|
|
2024
Q2 | $19.8M | Sell |
2,133,702
-846,645
| -28% | -$7.87M | 0.04% | 318 |
|
|
2024
Q1 | $29.5M | Buy |
2,980,347
+950,390
| +47% | +$9.42M | 0.05% | 255 |
|
|
2023
Q4 | $6.56M | Buy |
2,029,957
+1,203,862
| +146% | +$3.89M | 0.01% | 558 |
|
|
2023
Q3 | $4.39M | Sell |
826,095
-6,445
| -0.8% | -$34.2K | 0.01% | 607 |
|
|
2023
Q2 | $7.93M | Buy |
832,540
+346,300
| +71% | +$3.3M | 0.02% | 479 |
|
|
2023
Q1 | $5.35M | Buy |
486,240
+1,688
| +0.3% | +$18.6K | 0.01% | 547 |
|
|
2022
Q4 | $7.17M | Sell |
484,552
-4,793
| -1% | -$70.9K | 0.02% | 479 |
|
|
2022
Q3 | $9.35M | Buy |
489,345
+109,450
| +29% | +$2.09M | 0.02% | 383 |
|
|
2022
Q2 | $8.1M | Sell |
379,895
-115,555
| -23% | -$2.46M | 0.02% | 418 |
|
|
2022
Q1 | $9.54M | Buy |
495,450
+75,776
| +18% | +$1.46M | 0.02% | 435 |
|
|
2021
Q4 | $8.7M | Buy |
419,674
+29,736
| +8% | +$617K | 0.02% | 505 |
|
|
2021
Q3 | $9.32M | Sell |
389,938
-7,278
| -2% | -$174K | 0.02% | 449 |
|
|
2021
Q2 | $10.8M | Buy |
397,216
+226,013
| +132% | +$6.17M | 0.02% | 414 |
|
|
2021
Q1 | $4.95M | Buy |
171,203
+132,599
| +343% | +$3.84M | 0.01% | 624 |
|
|
2020
Q4 | $1.09M | Buy |
38,604
+16,728
| +76% | +$471K | ﹤0.01% | 1371 |
|
|
2020
Q3 | $641K | Buy |
21,876
+14,376
| +192% | +$421K | ﹤0.01% | 1462 |
|
|
2020
Q2 | $227K | Hold |
7,500
| – | – | ﹤0.01% | 1568 |
|
|
2020
Q1 | $224K | Buy |
+7,500
| New | +$224K | ﹤0.01% | 1519 |
|